Rachmilewitz D, Karmeli F, Schwartz L W, Simon P L
Department of Medicine, Hadassah University Hospital Mount Scopus, Hebrew University Hadassah Medical School, Jerusalem, Israel.
Gut. 1992 Jul;33(7):929-32. doi: 10.1136/gut.33.7.929.
The effect of 5-ASA and 4-ASA, drugs used for the treatment of inflammatory bowel disease, on modulation of experimental colitis and on colonic generation of interleukin-1 was evaluated. Three weeks of treatment with 5-ASA or 4-ASA (50 micrograms/kg) and one week of treatment with 5-ASA significantly decreased colonic interleukin-1 generation and the extent and severity of inflammation in a rat model of colitis induced by trinitrobenzene sulphonic acid. Colonic biopsies were obtained from patients with active ulcerative colitis and organ cultured 24 hours in the absence or presence of the following drugs: sulphasalazine, sulphapyridine, 5-ASA and 4-ASA (25-100 micrograms/ml). Interleukin-1 content in tissue cultured in the presence of 5-ASA (100 micrograms/ml) was two-thirds of its content in tissue cultured in drug free medium and its release into the medium was decreased by 50%. Sulphasalazine 50 micrograms/ml significantly decreased by 33% the tissue content but did not affect interleukin-1 release and a higher dose was not more effective. Sulphapyridine and 4-ASA in doses up to 100 micrograms/ml did not affect either interleukin-1 colonic content or its release into the culture medium. We conclude that pharmacological suppression of colonic interleukin-1 generation may be one, although not the sole mechanism to explain the therapeutic efficacy of 5-ASA in the treatment of inflammatory bowel disease.
评估了用于治疗炎症性肠病的5-氨基水杨酸(5-ASA)和4-氨基水杨酸(4-ASA)对实验性结肠炎的调节作用以及对结肠白细胞介素-1生成的影响。用5-ASA或4-ASA(50微克/千克)治疗三周以及用5-ASA治疗一周,可显著降低三硝基苯磺酸诱导的大鼠结肠炎模型中结肠白细胞介素-1的生成以及炎症的程度和严重程度。从活动性溃疡性结肠炎患者获取结肠活检组织,并在无或有以下药物存在的情况下进行24小时器官培养:柳氮磺胺吡啶、磺胺吡啶、5-ASA和4-ASA(25 - 100微克/毫升)。在5-ASA(100微克/毫升)存在下培养的组织中白细胞介素-1的含量是在无药物培养基中培养的组织中含量的三分之二,并且其释放到培养基中的量减少了50%。50微克/毫升的柳氮磺胺吡啶可使组织含量显著降低33%,但不影响白细胞介素-1的释放,更高剂量也没有更明显的效果。剂量高达100微克/毫升的磺胺吡啶和4-ASA既不影响结肠中白细胞介素-1的含量,也不影响其释放到培养基中。我们得出结论,对结肠白细胞介素-1生成的药理学抑制可能是解释5-ASA治疗炎症性肠病疗效的一种机制,尽管不是唯一机制。